GlaxoSmithKline plc Total Liabilities
GlaxoSmithKline plc total liabilities. Based on the latest financial reports, GlaxoSmithKline plc (GSKN) has total liabilities worth MX$45.59 Billion MXN (≈ $2.62 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GSKN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GlaxoSmithKline plc (2013–2024)
Total liabilities of GlaxoSmithKline plc from 2013 to 2024. This chart illustrates how GlaxoSmithKline plc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of GlaxoSmithKline plc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
GlaxoSmithKline plc Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GlaxoSmithKline PLC ADR
NYSE:GSK
|
USA | $44.29 Billion |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
Germany | €1.59 Trillion |
|
Rio Tinto Group
F:RIOA
|
Germany | €61.08 Billion |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
Germany | €895.38 Billion |
|
Medtronic PLC
NYSE:MDT
|
USA | $42.96 Billion |
|
China Life Insurance Co Ltd A
SHG:601628
|
China | CN¥7.10 Trillion |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
USA | $57.16 Billion |
|
Accenture plc
NYSE:ACN
|
USA | $35.79 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down GlaxoSmithKline plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GlaxoSmithKline plc asset portfolio.
Liquidity & Leverage Metrics
GlaxoSmithKline plc Total Liabilities Ratios Explained
GlaxoSmithKline plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline plc (2013–2024)
The table below shows the annual total liabilities of GlaxoSmithKline plc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | MX$46.38 Billion ≈ $2.67 Billion |
+0.36% |
| 2023-12-31 | MX$46.21 Billion ≈ $2.66 Billion |
-7.67% |
| 2022-12-31 | MX$50.05 Billion ≈ $2.88 Billion |
-13.35% |
| 2021-12-31 | MX$57.76 Billion ≈ $3.32 Billion |
-3.12% |
| 2020-12-31 | MX$59.62 Billion ≈ $3.43 Billion |
-2.79% |
| 2019-12-31 | MX$61.34 Billion ≈ $3.53 Billion |
+12.76% |
| 2018-12-31 | MX$54.39 Billion ≈ $3.13 Billion |
+2.84% |
| 2017-12-31 | MX$52.89 Billion ≈ $3.04 Billion |
-2.27% |
| 2016-12-31 | MX$54.12 Billion ≈ $3.11 Billion |
+21.43% |
| 2015-12-31 | MX$44.57 Billion ≈ $2.56 Billion |
+24.79% |
| 2014-12-31 | MX$35.72 Billion ≈ $2.06 Billion |
+4.20% |
| 2013-12-31 | MX$34.27 Billion ≈ $1.97 Billion |
-- |
About GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more